Clinical Trials
13
Active:2
Completed:4
Trial Phases
3 Phases
Early Phase 1:1
Phase 1:9
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Phase 1
9 (69.2%)Phase 2
3 (23.1%)Early Phase 1
1 (7.7%)Imaging of Solid Tumors Using 18F-TRX
Phase 1
Recruiting
- Conditions
- Solid TumorCastration-Resistant Prostate CarcinomaLocally Advanced Clear Cell Renal Cell CarcinomaSolid CarcinomaMetastatic Clear Cell Renal Cell CarcinomaMetastatic Malignant Solid NeoplasmStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Glioma, Malignant
- Interventions
- Drug: 18F-TRXProcedure: Positron Emission Tomography (PET)/Computerized tomography (CT)Procedure: Tumor BiopsyProcedure: Blood Specimen Collection
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-07-18
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 56
- Registration Number
- NCT06942104
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
64Cu-GRIP B in Patients With Advanced Malignancies
Phase 1
Recruiting
- Conditions
- Prostate CancerRenal CancerUrethral CancerAdvanced Solid TumorMetastatic Castration-resistant Prostate CancerSolid Tumor, Adult
- Interventions
- Drug: Copper-64 labeled Granzyme B (64Cu-GRIP B)Procedure: Positron Emission Tomography (PET)
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 91
- Registration Number
- NCT05888532
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1
Active, not recruiting
- Conditions
- Prostate CancerMetastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2025-08-27
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 44
- Registration Number
- NCT05011188
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
Phase 1
Terminated
- Conditions
- Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Metastatic Castration-resistant Prostate CancerCastration-Resistant Prostate CarcinomaStage IV Prostate Cancer AJCC v8Metastatic Prostate CarcinomaSolid Tumor, AdultSolid Tumor
- Interventions
- Procedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Optional Tumor Biopsy
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 2
- Registration Number
- NCT04927663
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostate CancerSmall Cell Neuroendocrine CarcinomaSmall Cell Carcinoma
- Interventions
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Rahul Aggarwal
- Target Recruit Count
- 2
- Registration Number
- NCT04926181
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
- Prev
- 1
- 2
- 3
- Next
News
No news found